A2A Pharma
- May 16, 2019
- 1 min read

A2A at Biopharma

Updated: Feb 7, 2020

A2A participated at the AI Applications Summit Biopharma discussing the urgency to advance AI applications in industry to bring benefits to patients faster

LEARN MORE

Recent Posts

A2A co-founded biomea Fusion raises $56M

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of

A2A / Daewoong Pharmaceutical Oncology Agreement

A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology Drug Discovery. LEARN MORE

A2A Appoints New Advisors

Dr. Siddhartha Mukherjee, Dr. Annalisa Jenkins and Dr. Srikumar Chellappan join A2A’s Advisory Board. LEARN MORE

A2A at Biopharma

A2A participated at the AI Applications Summit Biopharma discussing the urgency to advance AI applications in industry to bring benefits to patients faster

LEARN MORE

Recent Posts

menu

Contact